

Boschpharmaceuticals.com/frm.login.aspx

treatment discontinuation due to adverse effects was not more common with topiramate than with placebo in a pooled analysis of two rcts (lowstrength evidence)

boschpharmaceuticals.com

boschpharmaceuticals.com/frm.login.aspx